Top

Published in:

Open Access 01-12-2016 | Review

The role of adenosinergic pathway in human autoimmune diseases

Authors: Ke Dong, Zhao-wei Gao, Hui-zhong Zhang

Published in: Immunologic Research | Issue 5-6/2016

Abstract

Autoimmune diseases are characterized by the abnormal immune response against self-tissue, which are caused by the failure of nature immune homeostasis. Nature immune homeostasis represents the normal state of appropriate immune response to nonself-antigen and unresponsiveness to self-antigens. In normal situation, immune homeostasis is regulated by immunosuppressive signal and immunostimulating signal together. Accumulating data have demonstrated that the adenosinergic pathway played key roles in immune suppression and shield body from an excessive inflammatory response. The deficiency of adenosinergic pathway results in the imbalance between the pro- and anti-inflammatory activities. Thus, researchers pay much attention to the role of adenosinergic pathway in autoimmune diseases development. To date, accumulating data have suggested an important role of adenosinergic pathway-related molecules (i.e., CD39, CD73, ADA, adenosine receptors, etc.) in many types of human autoimmune diseases. More importantly, these findings have presented potential value of adenosinergic pathway analysis to be used for autoimmune diseases diagnosis, monitoring and treatment. In this review, we will provide a comprehensive description of the role of adenosinergic pathway in human autoimmune diseases.

Margo CE, Harman LE. Autoimmune disease: conceptual history and contributions of ocular immunology. Surv Ophthalmol. 2016;. doi:10.1016/j.survophthal.2016.04.006.PubMed

Liebman HA. Immune modulation for autoimmune disorders: evolution of therapeutics. Semin Hematol. 2016;53(Suppl 1):S23–6. doi:10.1053/j.seminhematol.2016.04.008.CrossRefPubMed

Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discovery. 2008;7(9):759–70. doi:10.1038/nrd2638.CrossRefPubMed

Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004;25(1):33–9.CrossRefPubMed

Wang D, Huang S, Yuan X, Liang J, Xu R, Yao G, et al. The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell Mol Immunol. 2015;. doi:10.1038/cmi.2015.89.

Ohl K, Tenbrock K. Regulatory T cells in systemic lupus erythematosus. Eur J Immunol. 2015;45(2):344–55. doi:10.1002/eji.201344280.CrossRefPubMed

Alunno A, Bartoloni E, Bistoni O, Nocentini G, Ronchetti S, Caterbi S, et al. Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. Clin Dev Immunol. 2012;2012:823085. doi:10.1155/2012/823085.CrossRefPubMedPubMedCentral

Yang J, Yang X, Zou H, Chu Y, Li M. Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus. Rheumatology (Oxford, England). 2011;50(8):1366–72. doi:10.1093/rheumatology/ker116.CrossRef

Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009;60(5):1472–83. doi:10.1002/art.24499.CrossRefPubMed

10.

Martin JC, Baeten DL, Josien R. Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus. Clin Immunol (Orlando, Fla). 2014;154(1):1–12. doi:10.1016/j.clim.2014.05.004.CrossRef

11.

Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4 + CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol (Baltimore, Md: 1950). 2007;178(4):2579–88.CrossRef

12.

Vincent FB, Northcott M, Hoi A, Mackay F, Morand EF. Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res Ther. 2013;15(4):R97. doi:10.1186/ar4277.CrossRefPubMedPubMedCentral

13.

Roeleveld DM, Koenders MI. The role of the Th17 cytokines IL-17 and IL-22 in Rheumatoid Arthritis pathogenesis and developments in cytokine immunotherapy. Cytokine. 2015;74(1):101–7. doi:10.1016/j.cyto.2014.10.006.CrossRefPubMed

14.

Gaffen SL. The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Curr Rheumatol Rep. 2009;11(5):365–70.CrossRefPubMedPubMedCentral

15.

Chen R, Tao Y, Qiu K, Huang W, Huang C, Li J. [Association of circulating Treg cells with disease activity in patients with rheumatoid arthritis]. Nan fang yi ke da xue xue bao = J South Med Univ. 2012;32(6):886–9.

16.

Cabrera SM, Rigby MR, Mirmira RG. Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. Curr Mol Med. 2012;12(10):1261–72.CrossRefPubMedPubMedCentral

17.

Antonioli L, Pacher P, Vizi ES, Hasko G. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2013;19(6):355–67. doi:10.1016/j.molmed.2013.03.005.CrossRefPubMedPubMedCentral

18.

Nguyen MD, Ross AE, Ryals M, Lee ST, Venton BJ. Clearance of rapid adenosine release is regulated by nucleoside transporters and metabolism. Pharmacol Res Perspect. 2015;3(6):e00189. doi:10.1002/prp2.189.CrossRefPubMedPubMedCentral

19.

Antonioli L, Fornai M, Colucci R, Ghisu N, Tuccori M, Del Tacca M, et al. Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications. Pharmacol Ther. 2008;120(3):233–53. doi:10.1016/j.pharmthera.2008.08.010.CrossRefPubMed

20.

Romio M, Reinbeck B, Bongardt S, Huls S, Burghoff S, Schrader J. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells. Am J Physiol Cell Physiol. 2011;301(2):C530–9. doi:10.1152/ajpcell.00385.2010.CrossRefPubMed

21.

Smyth LA, Ratnasothy K, Tsang JY, Boardman D, Warley A, Lechler R, et al. CD73 expression on extracellular vesicles derived from CD4 + CD25 + Foxp3 + T cells contributes to their regulatory function. Eur J Immunol. 2013;43(9):2430–40. doi:10.1002/eji.201242909.CrossRefPubMed

22.

Ohta A, Kini R, Ohta A, Subramanian M, Madasu M, Sitkovsky M. The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol. 2012;3:190. doi:10.3389/fimmu.2012.00190.CrossRefPubMedPubMedCentral

23.

Hasko G, Pacher P. Regulation of macrophage function by adenosine. Arterioscler Thromb Vasc Biol. 2012;32(4):865–9. doi:10.1161/atvbaha.111.226852.CrossRefPubMedPubMedCentral

24.

Liu C, Shang Q, Bai Y, Guo C, Zhu F, Zhang L, et al. Adenosine A2A receptor, a potential valuable target for controlling reoxygenated DCs-triggered inflammation. Mol Immunol. 2015;63(2):559–65. doi:10.1016/j.molimm.2014.10.012.CrossRefPubMed

25.

Chrobak P, Charlebois R, Rejtar P, El Bikai R, Allard B, Stagg J. CD73 plays a protective role in collagen-induced arthritis. J Immunol (Baltimore, Md: 1950). 2015;194(6):2487–92. doi:10.4049/jimmunol.1401416.CrossRef

26.

Peres RS, Liew FY, Talbot J, Carregaro V, Oliveira RD, Almeida SL, et al. Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis. Proc Natl Acad Sci USA. 2015;112(8):2509–14. doi:10.1073/pnas.1424792112.CrossRefPubMedPubMedCentral

27.

Vinapamula KS, Pemmaraju SV, Bhattaram SK, Bitla AR, Manohar SM. Serum adenosine deaminase as inflammatory marker in rheumatoid arthritis. J Clin Diagn Res JCDR. 2015;9(9):Bc08–10. doi:10.7860/jcdr/2015/14296.6483.PubMed

28.

Dolff S, Bijl M, Huitema MG, Limburg PC, Kallenberg CG, Abdulahad WH. Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus. Clin Immunol (Orlando, Fla). 2011;141(2):197–204. doi:10.1016/j.clim.2011.08.005.CrossRef

29.

Li DM, Li XP, Li XM, Wang GS, Ma Y, Zhao SS, et al. Expression of FOXP3 in CD4 + CD39 + T cells of patients with systemic lupus erythematosus and dynamic observation of treatment with glucocorticoid. Zhonghua yi xue za zhi. 2009;89(23):1636–8.PubMed

30.

Li DM, Li XP, Zhang JH, Hu SR, Xiao B, Chen W, et al. The expression of CD73 in CD4 + regulatory T cells in patients with new-onset systemic lupus erythematosus. Zhonghua nei ke za zhi. 2010;49(9):772–5.PubMed

31.

Saghiri R, Ghashghai N, Movaseghi S, Poursharifi P, Jalilfar S, Bidhendi MA, et al. Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern. Rheumatol Int. 2012;32(6):1633–8. doi:10.1007/s00296-011-1836-8.CrossRefPubMed

32.

Zhang L, Yang N, Wang S, Huang B, Li F, Tan H, et al. Adenosine 2A receptor is protective against renal injury in MRL/lpr mice. Lupus. 2011;20(7):667–77. doi:10.1177/0961203310393262.CrossRefPubMed

33.

Antonioli L, Blandizzi C, Csoka B, Pacher P, Hasko G. Adenosine signalling in diabetes mellitus–pathophysiology and therapeutic considerations. Nat Rev Endocrinol. 2015;11(4):228–41. doi:10.1038/nrendo.2015.10.CrossRefPubMed

34.

Andersson O. Role of adenosine signalling and metabolism in beta-cell regeneration. Exp Cell Res. 2014;321(1):3–10. doi:10.1016/j.yexcr.2013.11.019.CrossRefPubMed

35.

Nemeth ZH, Bleich D, Csoka B, Pacher P, Mabley JG, Himer L, et al. Adenosine receptor activation ameliorates type 1 diabetes. FASEB J. 2007;21(10):2379–88. doi:10.1096/fj.07-8213com.CrossRefPubMedPubMedCentral

36.

Ohtani M, Oka T, Ohura K. Possible involvement of A(2)A and A(3) receptors in modulation of insulin secretion and beta-cell survival in mouse pancreatic islets. Gen Comp Endocrinol. 2013;187:86–94. doi:10.1016/j.ygcen.2013.02.011.CrossRefPubMed

37.

Tai N, Wong FS, Wen L. TLR9 deficiency promotes CD73 expression in T cells and diabetes protection in nonobese diabetic mice. J Immunol (Baltimore, Md: 1950). 2013;191(6):2926–37. doi:10.4049/jimmunol.1300547.CrossRef

38.

Mills JH, Thompson LF, Mueller C, Waickman AT, Jalkanen S, Niemela J, et al. CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2008;105(27):9325–30. doi:10.1073/pnas.0711175105.CrossRefPubMedPubMedCentral

39.

Wei W, Du C, Lv J, Zhao G, Li Z, Wu Z, et al. Blocking A2B adenosine receptor alleviates pathogenesis of experimental autoimmune encephalomyelitis via inhibition of IL-6 production and Th17 differentiation. J Immunol (Baltimore, Md: 1950). 2013;190(1):138–46. doi:10.4049/jimmunol.1103721.CrossRef

40.

Johnston JB, Silva C, Gonzalez G, Holden J, Warren KG, Metz LM, et al. Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann neurol. 2001;49(5):650–8.CrossRefPubMed

41.

Tsutsui S, Schnermann J, Noorbakhsh F, Henry S, Yong VW, Winston BW, et al. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neuro sci off J Soc Neurosci. 2004;24(6):1521–9. doi:10.1523/jneurosci.4271-03.2004.CrossRef

42.

Link H, Xiao BG. Rat models as tool to develop new immunotherapies. Immunol Rev. 2001;184:117–28.CrossRefPubMed

43.

Chiba S, Matsumoto H, Motoi Y, Miyano N, Kashiwagi M. High serum adenosine deaminase activity and its correlation with lymphocyte subsets in myasthenia gravis. J Neurol Sci. 1990;100(1–2):174–7.CrossRefPubMed

44.

Oliveira L, Correia A. Deficits in endogenous adenosine formation by ecto-5′-nucleotidase/CD73 impair neuromuscular transmission and immune competence in experimental autoimmune myasthenia gravis. Mediators Inflamm. 2015;2015:460610. doi:10.1155/2015/460610.

45.

Li N, Mu L, Wang J, Zhang J, Xie X, Kong Q, et al. Activation of the adenosine A2A receptor attenuates experimental autoimmune myasthenia gravis severity. Eur J Immunol. 2012;42(5):1140–51. doi:10.1002/eji.201142088.CrossRefPubMed

46.

Li N, Wang G, Yao X, Kong Q, Shang X, Xie X, et al. Adenosine receptor expression in a rat model of experimental autoimmune myasthenia gravis. Cell Immunol. 2014;290(2):217–25. doi:10.1016/j.cellimm.2014.07.005.CrossRefPubMed

47.

Grant CR, Liberal R, Holder BS, Cardone J, Ma Y, Robson SC, et al. Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis. Hepatology (Baltimore, MD). 2014;59(3):1007–15. doi:10.1002/hep.26583.CrossRef

48.

Liberal R, Grant CR, Ma Y, Csizmadia E, Jiang ZG, Heneghan MA, et al. CD39 mediated regulation of Th17-cell effector function is impaired in juvenile autoimmune liver disease. J Autoimmun. 2016;. doi:10.1016/j.jaut.2016.05.005.

49.

Botta Gordon-Smith S, Ursu S, Eaton S, Moncrieffe H, Wedderburn LR. Correlation of low CD73 expression on synovial lymphocytes with reduced adenosine generation and higher disease severity in juvenile idiopathic arthritis. Arthritis Rheumatol (Hoboken, NJ). 2015;67(2):545–54. doi:10.1002/art.38959.CrossRef

50.

Liang D, Zuo A, Zhao R, Shao H, Born WK, O’Brien RL, et al. CD73 expressed on gammadelta T cells shapes their regulatory effect in experimental autoimmune uveitis. PLoS ONE. 2016;11(2):e0150078. doi:10.1371/journal.pone.0150078.CrossRefPubMedPubMedCentral

51.

Bar-Yehuda S, Luger D, Ochaion A, Cohen S, Patokaa R, Zozulya G, et al. Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101. Int J Mol Med. 2011;28(5):727–31. doi:10.3892/ijmm.2011.753.PubMedPubMedCentral

52.

Chen M, Liang D, Zuo A, Shao H, Kaplan HJ, Sun D. An A2B adenosine receptor agonist promotes Th17 autoimmune responses in experimental autoimmune uveitis (EAU) via dendritic cell activation. PLoS ONE. 2015;10(7):e0132348. doi:10.1371/journal.pone.0132348.CrossRefPubMedPubMedCentral

53.

Yip L, Taylor C, Whiting CC, Fathman CG. Diminished adenosine A1 receptor expression in pancreatic alpha-cells may contribute to the pathology of type 1 diabetes. Diabetes. 2013;62(12):4208–19. doi:10.2337/db13-0614.CrossRefPubMedPubMedCentral

54.

Chiba S, Saitoh M, Kashiwagi M, Kobayashi N, Matsumoto H. Isozyme analysis of the high serum adenosine deaminase activity in patients with myasthenia gravis. Intern Med (Tokyo, Japan). 1995;34(2):81–4.CrossRef

55.

Chouker A, Thiel M, Lukashev D, Ward JM, Kaufmann I, Apasov S, et al. Critical role of hypoxia and A2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway. Mol Med (Cambridge, Mass). 2008;14(3–4):116–23. doi:10.2119/2007-00075.Chouker.

56.

Fishman P, Cohen S. The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis. Clin Rheumatol. 2016;35(9):2359–62. doi:10.1007/s10067-016-3202-4.CrossRefPubMed

57.

Silverman MH, Strand V, Markovits D, Nahir M, Reitblat T, Molad Y, et al. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J Rheumatol. 2008;35(1):41–8.PubMed

Title: The role of adenosinergic pathway in human autoimmune diseases
Authors: Ke Dong
Zhao-wei Gao
Hui-zhong Zhang
Publication date: 01-12-2016
Publisher: Springer US
Published in: Immunologic Research / Issue 5-6/2016
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-016-8870-2

At a glance: The STEP trials

Springer Medicine

The role of adenosinergic pathway in human autoimmune diseases

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5-6/2016

Inflammasomes and its importance in viral infections

CD19+ Tim-1+ B cells are decreased and negatively correlated with disease severity in Myasthenia Gravis patients

Effect of continuous positive airway pressure (CPAP) therapy on IL-23 in patients with obstructive sleep apnea

Clinical association of mixed connective tissue disease and granulomatosis with polyangiitis: a case report and systematic screening of anti-U1RNP and anti-PR3 auto-antibody double positivity in ten European hospitals

Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis

Immunological characterization of the early human fracture hematoma